DOCSLIB.ORG

Antidepressant Utilisation and Incidence of Weight Gain During 10 Years' Follow-Up: Population Based Cohort Study

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antidepressant Utilisation and Incidence of Weight Gain During 10 Years' Follow-Up: Population Based Cohort Study RESEARCH Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study BMJ: first published as 10.1136/bmj.k1951 on 23 May 2018. Downloaded from Rafael Gafoor,1 Helen P Booth,1,2 Martin C Gulliford1,3 1School of Population Health ABSTRACT rate ratio for transition to overweight or obesity was and Environmental Sciences, OBJECTIVE 1.29 (1.25 to 1.34); in people who were initially King’s College London, London To evaluate the long term association between overweight, the adjusted rate ratio for transition to SE1 1UL, UK antidepressant prescribing and body weight. obesity was 1.29 (1.25 to 1.33). Associations may not 2Clinical Practice Research Datalink, Medicines and DESIGN be causal, and residual confounding might contribute Healthcare products Regulatory Population based cohort study. to overestimation of associations. Agency, London, UK CONCLUSION 3NIHR Biomedical Research SETTING Centre at Guy’s and St Thomas’ General practices contributing to the UK Clinical Widespread utilisation of antidepressants may be NHS Foundation Trust and Practice Research Datalink, 2004-14. contributing to long term increased risk of weight King’s College London, Guy’s gain at population level. The potential for weight gain PARTICIPANTS Hospital, London, UK should be considered when antidepressant treatment 136 762 men and 157 957 women with three or more Correspondence to: R Gafoor is indicated. [email protected] records for body mass index (BMI). Additional material is published online only. To view please visit MAIN OUTCOME MEASURES the journal online. The main outcomes were antidepressant prescribing, Introduction Cite this as: BMJ 2018;361:k1951 incidence of ≥5% increase in body weight, and Obesity is an increasing concern worldwide. Between http://dx.doi.org/10.1136/bmj.k1951 transition to overweight or obesity. Adjusted rate 1975 and 2014 the global prevalence of obesity Accepted: 13 April 2018 ratios were estimated from a Poisson model adjusting increased from 3.2% to 10.8% for men and from 6.4% for age, sex, depression recording, comorbidity, to 14.9% for women.1 The United States and United coprescribing of antiepileptics or antipsychotics, Kingdom have among the highest rates of obesity in the deprivation, smoking, and advice on diet. world: 69% of US adults are overweight or obese and 2 RESULTS 36% are obese, and 61% of UK adults are overweight In the year of study entry, 17 803 (13.0%) men and or obese, with the prevalence of obesity increasing 3 35 307 (22.4%) women with a mean age of 51.5 years from 15% in 1993 to 26% in 2016. Severe obesity is http://www.bmj.com/ (SD 16.6 years) were prescribed antidepressants. strongly associated with socioeconomic inequality in During 1 836 452 person years of follow-up, the both the US and the UK.4 Weight gain and obesity are incidence of new episodes of ≥5 weight gain in important public health problems, being associated participants not prescribed antidepressants was 8.1 with increased risk of chronic disease and mortality.5 6 per 100 person years and in participants prescribed Once obesity is established, it is difficult to achieve antidepressants was 11.2 per 100 person years substantial and sustained weight loss.7 (adjusted rate ratio 1.21, 95% confidence interval Antidepressants are increasingly being prescribed.8 on 2 October 2021 by guest. Protected copyright. 1.19 to 1.22, P<0.001). The risk of weight gain In a primary care population 23% of 1.5 million remained increased during at least six years of follow- participants were prescribed an antidepressant on up. In the second year of treatment the number of at least one occasion between 1995 to 2011.9 The participants treated with antidepressants for one number of antidepressant prescriptions issued nearly year for one additional episode of ≥5% weight gain doubled over the same period, although some of the was 27 (95% confidence interval 25 to 29). In people increase might be explained by extended duration who were initially of normal weight, the adjusted of courses of treatment.9 Obesity is associated with depression, which is particularly common in patients with severe obesity.10 11 Antidepressant treatment WHat IS ALREADY KNOWN ON THIS TOPIC may also be associated with weight gain,12 through 13 Obesity is global and antidepressant use is increasingly widespread mechanisms that are only partially understood. The Short term studies suggest strong associations between antidepressant use and current high prevalence of antidepressant use could weight gain have potentially important public health impacts through the association with body weight gain, but No robust data exist on the long term risks of weight gain or the relative risks of the nature of this association is poorly described. weight gain for individual antidepressants Although a systematic review of antidepressant use WHat THIS stUDY ADDS and weight gain collated evidence from 116 clinical 14 Antidepressant treatment is associated with a sustained increase in risk of trials and clinical cohort studies, fewer than half weight gain over at least five years of the studies contributed data for more than three months of follow-up and it was not reported how many Associations with subsequent weight gain appear to vary widely within and studies included more than 12 months of follow-up. between antidepressant classes The review also drew attention to the heterogeneity Risk of weight gain should be considered when antidepressants are to be among different antidepressant drugs, with bupropion prescribed and fluoxetine being associated with lower weight gain the bmj | BMJ 2018;361:k1951 | doi: 10.1136/bmj.k1951 1 RESEARCH than mirtazapine and nortriptyline.14 Most studies we selected a random sample of up to a maximum of have reported on weight change in depressed patients 30 000 participants from each category of BMI and sex, BMJ: first published as 10.1136/bmj.k1951 on 23 May 2018. Downloaded from treated in clinical settings, but few population based resulting in 314 477 participants, for whom data were studies have investigated the potential population extracted for 314 449 participants. Fewer than 30 000 impact of widespread antidepressant treatment on women had a BMI of ≥45 and fewer than 30 000 men weight gain. One study evaluated weight change had a BMI of ≥40. We then extracted full CPRD records after initiation of antidepressant treatment in 5932 for this sample. In the analysis phase we computed patients registered with the Group Health system in additional BMI values from recorded weight and Washington state, USA, and found that weight gain height, permitting a greater number of participants to persisted for at least two years.15 A UK study analysed be represented in some BMI categories. We excluded data for 268 patients treated with antidepressants from participants with no BMI records for 1 November 2004 a general practice with 11 994 registered patients, to 31 October 2014. and concluded that weight gain persisted during long term treatment, with, in some instances, prescriptions Main outcome measures maintained for several years.16 Another US study Antidepressant prescriptions were the exposure evaluated weight gain in the 12 months after initiation of interest. We initially classified these according of antidepressant treatment in 22 610 adults treated to section 4.3 of the British National Formulary,20 in clinics in New England and found differences in the including tricyclic and related antidepressants (TCAs), propensity of individual antidepressants to result in monoamine oxidase inhibitors (MAOIs), selective weight gain.17 serotonin reuptake inhibitors (SSRIs), serotonin- In this study we used primary care electronic health noradrenaline (norepinephrine) reuptake inhibitors records to evaluate non-randomised evidence on the (SNRIs), and other antidepressant drugs. We then long term association of antidepressant prescribing analysed individual antidepressant drugs: mirtazapine, with weight gain. We also evaluated the associations duloxetine, sertraline, venlafaxine, citalopram, in different subgroups and whether individual fluoxetine, escitalopram, trazodone, amitriptyline, antidepressant drugs might be associated with greater paroxetine, nortriptyline, and dosulepin. risks of weight gain. Body weight was the outcome of interest. We evaluated all records of body weight, height, and BMI. Methods If a body weight value was recorded that indicated a ≥ Data source weight increase of 5% compared with the previous http://www.bmj.com/ We carried out a population based cohort study in the year, we classified the calendar year as being associated UK Clinical Practice Research Datalink (CPRD). The with weight gain. In the analysis we retained person CPRD is one of the world’s largest databases of primary time not associated with recorded body weight values, care electronic health records, with participation incorporating the assumption that weight gain had of about 7% of UK general practices and with not occurred. In a sensitivity analysis, we excluded ongoing collection of anonymised data from 1990. person time with no weight records, so as to provide a The registered active CPRD population is generally “complete case” analysis. on 2 October 2021 by guest. Protected copyright. representative of the UK population in terms of age, We included several variables as known sex, and regional distribution.18 During 2004-14, confounders or effect modifiers in the relation between the annual count of the CPRD registered
Load more

Recommended publications
  • Formulary and Prescribing Guidelines
    Formulary and Prescribing Guidelines SECTION 1: TREATMENT OF DEPRESSION Section 1. Treatment of depression 1.1 Introduction This guidance should be considered as part of a stepped care approach in the management of depressive disorders. Antidepressants are not routinely recommended for persistent sub-threshold depressive symptoms or mild depression but can be considered in these categories where there is a past history of moderate or severe depression, initial presentation of sub-threshold depressive symptoms for at least 2 years, and persistence of either mild or sub-threshold depression after other interventions1 have failed. The most current NICE guidance should be consulted wherever possible to obtain the most up to date information. For individuals with moderate or severe depression, a combination of antidepressant medication and a high intensity psychological intervention (CBT or IPT) is recommended. When depression is accompanied by symptoms of anxiety, usually treat the depression first. If the person has an anxiety disorder and co-morbid depression or depressive symptoms, consider treating the anxiety first. Also consider offering advice on sleep hygiene, by way of establishing regular sleep and wake times; avoiding excess eating, avoiding smoking and drinking alcohol before sleep; and taking regular physical exercise if possible. Detailed information on the treatment of depression in children and adolescents can be found in section 12. Further guidance on prescribing for older adults and for antenatal/postnatal service users can be found in section 11 and section 20, respectively. 1.2 Approved Drugs for the treatment of Depression in Adults For licensing indications, see Annex 1 Drug5 Formulation5 Comments2,3,4 Caps 20mg, 60mg Selective serotonin reuptake inhibitor (SSRI) Fluoxetine Liquid 20mg/5ml 1st line SSRI (based on acquisition cost) Tabs 10mg, 25mg, 50mg Amitriptyline Tricyclic (TCA).
    [Show full text]
  • Duloxetine for Chronic Pain Relief
    Patient Information Leaflet Duloxetine for Chronic Pain Relief Produced By: Chronic Pain Service April 2014 Review due April 2017 1 If you require this leaflet in another language, large print or another format, please contact the Quality Team, telephone 01983 534850, who will advise you. Duloxetine ( Cymbalta ) is a medicine used to relieve chronic pain and treat low mood. It is often helpful for nerve-related pain or pain sensitivity (also called central sensitisation ). It has a different way of relieving pain than standard pain killers and is often prescribed in combination. If used for pain other than diabetes-related neuropathic pain it is formally used outside it’s product license as per individual decision by your pain specialist/doctor. As it affects the central nervous system in complex ways, the effect often takes a while to be felt and requires regular intake . We recommend a trial of at least four weeks to judge the effect. If good, it should be taken on a regular long-term basis; if there is no distinct relief it should be discontinued after the trial period. If you suffer with seizures/epilepsy, glaucoma and poorly controlled high blood pressure, Duloxetine should be used with caution and at a lower dose (up to 60mg per day). The most common side effect is drowsiness/dizziness therefore it is best time to take it in the evening. There are many other possible side effects, but most are uncommon, rare or very rare (please take a look at the product leaflet) We suggest that you avoid driving for at least 2 days after starting or increasing the dose of this medication.
    [Show full text]
  • Milnacipran for Pain in Fibromyalgia in Adults
    Milnacipran for pain in fibromyalgia in adults (Review) Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 10 http://www.thecochranelibrary.com Milnacipran for pain in fibromyalgia in adults (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 6 OBJECTIVES ..................................... 7 METHODS ...................................... 7 RESULTS....................................... 9 Figure1. ..................................... 10 Figure2. ..................................... 12 Figure3. ..................................... 13 Figure4. ..................................... 14 Figure5. ..................................... 18 DISCUSSION ..................................... 21 AUTHORS’CONCLUSIONS . 22 ACKNOWLEDGEMENTS . 23 REFERENCES ..................................... 23 CHARACTERISTICSOFSTUDIES . 27 DATAANDANALYSES. 38 Analysis 1.1. Comparison 1 Milnacipran 100 mg/day versus placebo, Outcome 1 At least 30% pain relief. 39 Analysis 1.2. Comparison 1 Milnacipran 100 mg/day versus placebo, Outcome 2 PGIC ’much improved’ or ’very much improved’.................................... 40 Analysis 1.3. Comparison
    [Show full text]
  • Adverse Effects of First-Line Pharmacologic Treatments of Major Depression in Older Adults
    Draft Comparative Effectiveness Review Number xx Adverse Effects of First-line Pharmacologic Treatments of Major Depression in Older Adults Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov This information is distributed solely for the purposes of predissemination peer review. It has not been formally disseminated by the Agency for Healthcare Research and Quality. The findings are subject to change based on the literature identified in the interim and peer-review/public comments and should not be referenced as definitive. It does not represent and should not be construed to represent an Agency for Healthcare Research and Quality or Department of Health and Human Services (AHRQ) determination or policy. Contract No. 290-2015-00012I Prepared by: Will be included in the final report Investigators: Will be included in the final report AHRQ Publication No. xx-EHCxxx <Month, Year> ii Purpose of the Review To assess adverse events of first-line antidepressants in the treatment of major depressive disorder in adults 65 years or older. Key Messages • Acute treatment (<12 weeks) with o Serotonin norepinephrine reuptake inhibitors (SNRIs) (duloxetine, venlafaxine), but not selective serotonin reuptake inhibitors (SSRIs) (escitalopram, fluoxetine) led to a greater number of adverse events compared with placebo. o SSRIs (citalopram, escitalopram and fluoxetine) and SNRIs (duloxetine and venlafaxine) led to a greater number of patients withdrawing from studies due to adverse events compared with placebo o Details of the contributing adverse events in RCTs were rarely reported to more clearly characterize what adverse events to expect.
    [Show full text]
  • Cymbalta (Duloxetine Hcl) Prior Authorization of Benefits Form
    Cymbalta (Duloxetine HCl) Prior Authorization of Benefits Form CONTAINS CONFIDENTIAL PATIENT INFORMATION Complete form in its entirety and fax to: Prior Authorization of Benefits Center at 844-512-9005 for retail pharmacy or 844-512-7027 for medical injectable. 1. Patient information 2. Physician information Patient name: _________________________________ Prescribing physician: _______________________________ Patient ID #: __________________________________ Physician address: _________________________________ Patient DOB: _________________________________ Physician phone #: _________________________________ Date of Rx: ___________________________________ Physician fax #: ____________________________________ Patient phone #: _______________________________ Physician specialty: _________________________________ Patient email address: __________________________ Physician DEA: ____________________________________ Physician NPI #: ___________________________________ Physician email address: ____________________________ 3. Medication 4. Strength 5. Directions 6. Quantity per 30 days Cymbalta (Duloxetine HCl) ______________________ _____________________ Specify: ________________________ 7. Diagnosis: ____________________________________________________________________________________ 8. Approval criteria: (Check all boxes that apply. Note: Any areas not filled out are considered not applicable to your patient and may affect the outcome of this request.) Major depressive disorder (MDD), depressive disorder or dysthymia: □ Yes □ No Patient has
    [Show full text]
  • Thioridazine-Induced Diarrhoea Protected by Copyright
    Postgrad Med J: first published as 10.1136/pgmj.51.593.182 on 1 March 1975. Downloaded from 182 Case reports Acknowledgments DAWSON, I.M.P., CORNES, J.S. & MORSON, B.C. (1961) We wish to thank Dr L. Henry, Consultant Pathologist, for Primary malignant lymphoid tumours of the intestinal his help and advice, the Photography Department for the tract. Report of 37 cases with a study of factors influencing illustration, Dr J. K. Barkla, Leader, Biomedical Informa- prognosis. British Journal of Surgery, 49, 80. tion Project, University of Sheffield, for helping in a search EHRLICH, A.N., STALDER, G., GELLER, W. & SHERLOCK, P. of the literature aided by UK Medlars, and Mr D. H. (1968) Gastrointestinal manifestations of malignant lym- Randall, Consultant Surgeon, Royal Infirmary, and Professor phoma. Gastroenterology, 54, 1115. H. L. Duthie, Professor of Surgery, for their advice. PIMPARKAR, B.D. (1964) Gastroenterology (Ed. by Henry L. Bockus), Volume II, p. 138. W. B. Saunders and Company: Philadelphia and London. References PORTMANN, U.V., DUNNE, E.F. & HAZARD, J.B. (1954) AL-BAHRANI, S.R. & BAKIR, F. (1971) Primary intestinal Manifestations of Hodgkin's disease of the gastrointestinal lymphoma. A challenging problem in abdominal pain. tract. American Journal of Roentgenology, Radiotherapy Annals of the Royal College of Surgeons, 49, 103. and Nuclear Medicine, 72, 772. BALIKIAN, J.P., NASsAR, N.T., SHAMMA'A, M.H. & SHAHID, WHITMORE, W.H. (1948) Duodenal diverticula with ulcera- K.J. (1969) Primary lymphomas of the small intestine in- tion. American Journal of Roentgenology, Radiotherapy cluding the duodenum. A roentgen analysis of 29 cases.
    [Show full text]
  • Medication Guide Duloxetine Delayed-Release Capsules, USP (Doo-LOX
    Medication Guide Duloxetine Delayed-Release Capsules, USP (doo-LOX-e-teen) Read this Medication Guide before you start taking duloxetine delayed-release capsules and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. Talk to your healthcare provider about: • all risks and benefits of treatment with antidepressant medicines • all treatment choices for depression or other serious mental illness What is the most important information I should know about antidepressant medicines, depression, other serious mental illnesses, and suicidal thoughts or actions? 1. Duloxetine delayed-release capsules and other antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, or young adults within the first few months of treatment or when the dose is changed. 2. Depression and other serious mental illnesses are the most important causes of suicidal thoughts or actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have (or have a family history of) bipolar illness (also called manic-depressive illness). 3. How can I watch for and try to prevent suicidal thoughts and actions? • Pay close attention to any changes in mood, behavior, actions, thoughts, or feelings, especially sudden changes. This is very important when an antidepressant medicine is started or when the dose is changed. • Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings. • Keep all follow-up visits with your healthcare provider as scheduled.
    [Show full text]
  • Nortriptyline the Missed Dose
    Version . June become pregnant in the future • If you have had a heart attack recently or have any heart problems • If you have a history of epilepsy or fits • If you have glaucoma • If you have difficulty in passing water • If you have thyroid disease • If you have or have had a mental health problem • If you are taking an antidepressant medicine, especially one called a Informati on for Adult Pati ents monoamine oxidase inhibitor (MAOI) Prescribed What if I forget or miss a dose? • Take it as soon as you remember. • If you only take one dose at bedtime and you miss the dose, do not take the medicine in the morning. Wait until the next night and skip Nortriptyline the missed dose. • Do not take two doses together. What if I want to stop taking nortriptyline? for • If you stop taking nortriptyline suddenly, you might experience withdrawal symptoms. Speak to your healthcare professional (doctor, nurse, pharmacist) who will be able to supervise a gradual reduction. the Treatment of Pain This information is not intended to replace your doctor’s advice. We advise you to read the manufacturer’s information for patients, which will be supplied by your pharmacist when your medicine is dispensed. Keep all medicines away from children,vulnerable adults or pets. Date Morning Lunch Tea time Night Further information: http://www.fpm.ac.uk/faculty-of-pain-medicine/patient-information Why have I been prescribed nortriptyline? doctor may need to increase the dose to get the maximum effect • Nortriptyline is used to treat many types of persistent pain.
    [Show full text]
  • Tcas Versus Placebo - New Studies in the Guideline Update
    TCAs versus placebo - new studies in the guideline update Comparisons Included in this Clinical Question Amitriptyline vs placebo Clomipramine vs placebo Dosulepin (dothiepin) vs placebo AMSTERDAM2003A LARSEN1989 FERGUSON1994B BAKISH1992B PECKNOLD1976B ITIL1993 BAKISH1992C RAMPELLO1991 MINDHAM1991 BREMNER1995 THOMPSON2001B CLAGHORN1983 CLAGHORN1983B FEIGHNER1979 GELENBERG1990 GEORGOTAS1982A GOLDBERG1980 HICKS1988 HOLLYMAN1988 HORMAZABAL1985 HOSCHL1989 KLIESER1988 LAAKMAN1995 LAPIERRE1991 LYDIARD1997 MYNORSWALLIS1995 MYNORSWALLIS1997 REIMHERR1990 RICKELS1982D RICKELS1985 RICKELS1991 ROFFMAN1982 ROWAN1982 SMITH1990 SPRING1992 STASSEN1993 WILCOX1994 16 Imipramine vs placebo BARGESCHAAPVELD2002 BEASLEY1991B BOYER1996A BYERLEY1988 CASSANO1986 CASSANO1996 CLAGHORN1996A COHN1984 COHN1985 COHN1990A COHN1992 COHN1996 DOMINGUEZ1981 DOMINGUEZ1985 DUNBAR1991 ELKIN1989 ENTSUAH1994 ESCOBAR1980 FABRE1980 FABRE1992 FABRE1996 FEIGER1996A FEIGHNER1980 FEIGHNER1982 FEIGHNER1983A FEIGHNER1983B FEIGHNER1989 FEIGHNER1989A FEIGHNER1989B FEIGHNER1989C FEIGHNER1992B FEIGHNER1993 FONTAINE1994 GELENBERG2002 GERNER1980B HAYES1983 ITIL1983A KASPER1995B KELLAMS1979 LAIRD1993 LAPIERRE1987 LECRUBIER1997B LIPMAN1986 LYDIARD1989 MARCH1990 17 MARKOWITZ1985 MENDELS1986 MERIDETH1983 Nortriptyline vs placebo NANDI1976 GEORGOTAS1986A NORTON1984 KATZ1990 PEDERSEN2002 NAIR1995 PESELOW1989 WHITE1984A PESELOW1989B PHILIPP1999 QUITKIN1989 RICKELS1981 RICKELS1982A RICKELS1987 SCHWEIZER1994 SCHWEIZER1998 SHRIVASTAVA1992 SILVERSTONE1994 SMALL1981 UCHA1990 VERSIANI1989 VERSIANI1990
    [Show full text]
  • 3,2,4 Tricyclic Antidepressants and the Risk of Congenital Malformation
    Tricyclic antidepressants and the risk of congenital malformations CONFIDENTIAL Medicines Adverse Reactions Committee Meeting date 3/12/2020 Agenda item 3.2.4 Title Tricyclic antidepressants and the risk of congenital malformations Submitted by Medsafe Pharmacovigilance Paper type For advice Team Active ingredient Product name Sponsor Amitriptyline Arrow-Amitriptyline Film coated tablet, 10 mg, 25 Teva Pharm (NZ) Ltd mg & 50 mg Amirol Film coated tablet, 10 mg & 25 mg AFT Pharmaceuticals Ltd Clomipramine Apo-Clomipramine Film coated tablet, 10 mg & Apotex NZ Ltd 25 mg Anafranil Tablet, 10 mg Section 29 Dosulepin Dosulepin Mylan Film coated tablet, 75 mg Mylan New Zealand Ltd Dosulepin Mylan Capsule, 25 mg Section 29 Doxepin Anten 50 Capsule, 50 mg Mylan New Zealand Ltd Imipramine Tofranil Coated tablet, 10 mg & 25 mg AFT Pharmaceuticals Ltd Nortriptyline Norpress Tablet, 10 mg & 25 mg Mylan New Zealand Ltd PHARMAC funding Product highlighted in bold above are funded on the Community Schedule. Two products (shown in italics) are funded but only available under Section 29 of the Medicines Act (ie, the products have not been approved by Medsafe). Previous MARC In utero exposure to serotonin reuptake inhibitors and risk of congenital meetings abnormalities 141st meeting March 2010 International action None Prescriber Update The use of antidepressants in pregnancy September 2010 Classification Prescription medicine Usage data The following pregnancy usage data for 2019 was obtained from the National Collections using the Pharmaceutical Dispensing in Pregnancy application in Qlik. The table shows the total number of dispensings, repeat dispensings and number of pregnancies exposed during first trimester (defined as 30 days prior to the estimated pregnancy start date to week 13) for pregnancies that ended in 2019.
    [Show full text]
  • Nortriptyline
    Starting dose Follow these instructions when first starting Nortriptyline. By slowly increasing the dose over a month, you are less likely to experience side- effects. If you have any problems at any time, drop back to the previous dose and continue with that dose (without increasing it any further). Bòrd SSN nan Eilean Siar If you achieve pain relief at a lower dose (e.g. 10mg or 20mg), you can continue NHS Western Isles taking the lower dose. You don’t have to increase the dose any further. Initial Dose Increase Dose (once before bedtime) Week 1 & 2 10mg Week 3 & 4 20mg Month 2 30mg Month 3 40mg Nortriptyline Note. Consult your GP for further dose increases. Western Isles Pain Management Service Remember to ensure you have enough medication especially coming up to weekends or public holidays. Should you wish to ask any further questions about your medication, please speak to your GP, community nurse or pharmacist. We are listening - how did we do? We welcome your feedback as it helps us evaluate the services we provide. If you would like to tell us about your experience: • speak to a member of staff • visit our website www.wihb.scot.nhs.uk/feedback or share your story at: www.careopinion.org.uk or 0800 122 31 35 • Tel. 01851 704704 (ext 2408) on a Tuesday and Friday afternoon between 1pm and 4pm. Date Produced: November 2018 Review Date: November 2020 Produced by: Dr. David Rigby, NHS Western Isles Disclaimer The content of this leaflet is intended to augment, not replace, information provided by your clinician.
    [Show full text]
  • Nortriptyline
    Nortriptyline This sheet talks about exposure to nortriptyline in pregnancy and while breastfeeding. This information should not take the place of medical care and advice from your healthcare provider. What is nortriptyline? Nortriptyline is a prescription medication that has been approved to treat depression. It is part of a group of medications called tricyclic antidepressants. Nortriptyline has also been used for other medical indications, such as attention deficit hyperactivity disorder (ADHD), eating disorders, irritable bowel syndrome, pain, and other disorders. Some trade names for nortriptyline are Aventyl® and Pamelor®. I take nortriptyline. Can it make it harder for me to get pregnant? Studies have not been done to see if nortriptyline could make it harder for a woman to get pregnant. Untreated psychiatric disorders and symptoms may affect fertility. I just found out I am pregnant. Should I stop taking nortriptyline? Do not change how you are taking this medication without talking to your healthcare provider, who will also discuss the risks of not taking nortriptyline. For some women, the benefits of staying on an antidepressant during pregnancy can outweigh the potential risks. If you plan to stop this medication, your healthcare provider might suggest that you gradually lower the dose instead of stopping all at once. Stopping this medication suddenly can cause some people to have withdrawal symptoms. Some people may have a relapse of their symptoms if they stop this medication during pregnancy. Does taking nortriptyline during pregnancy increase the chance of miscarriage? Miscarriage may occur in any pregnancy. There are no studies looking at whether the use of nortriptyline in pregnancy increases the chances for miscarriage.
    [Show full text]